Mursla Unveils New Bead-Nanochip Technology for Ultra-Sensitive, High-Throughput Detection of Exosomes


CAMBRIDGE, England–(BUSINESS WIRE)–Mursla, a new multi-omics exosome characterization company, is pleased to introduce its novel nanochip-based technology, as detailed in the preprint* “An Electro-Optical Bead Nanochip Technology for Ultrasensitive and Multidimensional Analysis of Small Extracellular Vesicles and Their Markers”, published today.This technology is part of Mursla’s ExoPheno™ platform.

Key features of the technology include:

  • Ultrasensitive detection of target exosomes and their markers.

  • Compatibility with clinical practices in a high throughput format.

  • Determination of new dimensions of exosomes allowing new research and clinical applications.

  • Presenting a roadmap for near-absolute quantification of target exosomes and detection of single exosomes.

This ultra-sensitive technology is called NEXOS (Nanoparticle EXOsome Sensing). It includes two methods, the first is a new patented and scalable nanoelectronic method, E-NEXOS, and the second is a high-throughput optical detection method, O-NEXOS. Both share the same steps for immunocapture and antibody labeling of exosomes and can be combined to derive differentiated detection parameters.

Dr Tomás Dias (PhD), CTO, Mursla commented : “To advance the understanding of exosome biology and their implications in disease, new tools are needed. NEXOS technology offers ultra-sensitive and original characterization metrics with the aim of disrupting many exosome applications. The reported study is the result of work carried out by Mursla’s multidisciplinary team.

NEXOS is part of Mursla’s ExoPheno™ platform and was designed to improve the translation of exosome-based diagnostics into clinics.

Pierre Arsène, Founder and CEO, Mursla added: “We believe that proper analysis of exosome biology in patients leads to breakthrough diagnostic solutions. This is now an engineering problem and our new technology based on nanoelectronics is helping to overcome the remaining technical hurdles around sensitivity and clinical compatibility.

* Preprints are used to speed up scientific communication and are usually subsequently submitted to peer-reviewed journals.


Source link


Comments are closed.